Physician profile
Michael L Kay
NPI 1467441972
$2,031.86
in general payments reported to CMS, 2019-2025
24 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $37.94 · 2021: $520 · 2022: $259 · 2023: $242 · 2024: $360 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $356.85 | 2021-2022 | |
| Alcon Vision LLC | $322.37 | 2019-2025 | Eysuvis, Tryptyr, Clareon |
| Allergan, INC. | $211.65 | 2019-2021 | |
| Oyster Point Pharma, INC. | $145.60 | 2022-2023 | Tyrvaya |
| Rxsight INC | $127.23 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Eyevance Pharmaceuticals LLC | $123.98 | 2021 | |
| New World Medical,INC. | $120.48 | 2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
| Ortho-Clinical Diagnostics, INC. | $109.88 | 2024 | Inflammadry |
| Harrow Eye, LLC | $75.90 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $53.07 | 2021-2025 | |
| Abbvie INC. | $51.62 | 2022-2025 | |
| Biotissue Holdings INC. | $44.93 | 2019-2020 | |
| Amgen INC. | $40.58 | 2024 | Tepezza |
| Sun Pharmaceutical Industries INC. | $36.24 | 2021-2022 | |
| Coopervision INC. | $35.99 | 2024-2025 | Myday Contact Lens |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $25.50 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $24.32 | 2019 | |
| Alimera Sciences, INC. | $24.30 | 2023 | Yutiq |
| Apellis Pharmaceuticals, INC. | $21.93 | 2025 | Syfovre |
| Genentech USA, INC. | $18.85 | 2023 | Vabysmo |
| Omeros Corporation | $15.93 | 2020 | |
| Horizon Therapeutics Plc | $15.72 | 2022 | |
| Bausch & Lomb Americas INC. | $14.78 | 2025 | Miebo |
| Mallinckrodt Hospital Products INC. | $14.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.